BioSpace News Archive

Moderna, Inc. today announced that as part of its commitment to sustainability, the Company will work to achieve net-zero carbon emissions globally by 2030.

A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid tumors.

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937

Rhizen Pharma commences dosing in a phase I/Ib trial to evaluate its novel PARP inhibitor (RP12146) in patients with advanced cancers.

Centessa Pharmaceuticals plc today announced proof-of-mechanism data from the first three subjects dosed in the ongoing repeat dose Phase 1 Part B study of ZF874 in subjects carrying at least one Z-mutated alpha-1-antitrypsin allele (PiXZ).

Prof. Niraj Varma & Dr. Kevin Campbell will help guide the development of new products as the company expands capabilities and continues to lead innovation in remote monitoring and AI

Titan Medical Inc. today announced that the company plans to issue its third quarter 2021 financial results prior to market opening on Thursday, November 11, 2021.

Coya Therapeutics, Inc. today announced the appointment of Adrian Hepner, M.D., Ph.D. as Chief Medical Officer and Greg MacMichael, Ph.D. as Chief Technical Officer, effective immediately.

Checkmate Pharmaceuticals, Inc. today announced that final clinical data from the Phase 1b study, CMP-001-001, of vidutolimod, an advanced generation Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab or as a monotherapy will be presented at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held in person and virtually November 10-14, 2021.

Vaccinex, Inc. today announced that Maurice Zauderer, Ph.D., President and Chief Executive officer, will participate in a Clinical Trials Roundup Session at the Virtual Huntington Study Group (HSG) Meeting at 3:15 p.m. ET on Friday, November 5, 2021.